Date Insider Type Main position Quantity % Market Cap.
23-11-16Issuer sale

CHIEF BUSINESS OFFICER

71,645 0.2929%
23-11-16Issuer sale

Director

27,380 0.1119%
23-11-16Issuer sale

Chairman

483,741 1.9774%
Change 5-day change 1-year change 3-year change Capi.($)
-17.95%-19.50% - - 16.15M
+0.64%-1.23%+55.95%+110.45% 52.88B
+8.55%+17.52%+72.65%+82.31% 50.98B
-0.45%-2.18%-14.16%-15.80% 22.81B
+1.28%+5.09%-2.30%+418.34% 22.43B
+2.03%+7.40%+28.79%-13.91% 17.01B
-0.73%+4.12%+28.77%-34.82% 15.91B
+2.98%+0.82%+15.64%+166.21% 13.29B
+5.94%+14.85%+134.05%+296.09% 13.58B
-0.71%+1.98%+78.88%+114.48% 11.75B
Average +0.16%+5.20%+44.25%+124.82% 24.52B
Weighted average by Cap. +2.82%+5.40%+46.19%+117.12%
Logo Acer Therapeutics Inc.
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Employees
33
  1. Stock Market
  2. Stocks
  3. ACER Stock